Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
Trial details
- Registry ID
- NCT05727904
- Phase
- Phase 3
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.NCT05727904 | IOVA | Phase 3 | Recruiting | 2028-03-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |